Total for the last 12 months
number of access : ?
number of downloads : ?
ID 114504
Tanaka, Atsushi Saga University
Inoue, Teruo Dokkyo Medical University
Kitakaze, Masafumi National Cerebral and Cardiovascular Center
Oyama, Jun‑ichi Saga University
Taguchi, Isao Dokkyo Medical University
Shimizu, Wataru Nippon Medical School
Watada, Hirotaka Juntendo University
Tomiyama, Hirofumi Tokyo Medical University
Ako, Junya Kitasato University
Sakata, Yasushi Osaka University
Anzai, Toshihisa National Cerebral and Cardiovascular Center
Uematsu, Masaaki Kansai Rosai Hospital
Suzuki, Makoto Kameda Medical Center
Eguchi, Kazuo Jichi Medical University
Yamashina, Akira Tokyo Medical University
Saito, Yoshihiko Nara Medical University
Sato, Yasunori Chiba University
Ueda, Shinichiro University of the Ryukyus
Murohara, Toyoaki Nagoya University
Node, Koichi Saga University
Chronic heart failure
SGLT2 inhibitor
Type 2 diabetes mellitus
Content Type
Journal Article
Background: Because type 2 diabetes mellitus is associated strongly with an increased risk of cardiovascular diseases, the number of patients with diabetes with chronic heart failure is increasing steadily. However, clinical evidence of therapeutic strategies in such patients is still lacking. A recent randomized, placebo-controlled trial in patients with type 2 diabetes with high cardiovascular risk demonstrated that the SGLT2 inhibitor, empagliflozin, reduced the incidence of hospitalization for heart failure. Because SGLT2 inhibitors cause a reduction in body weight and blood pressure in addition to improving glycemic control, they have the potential to exert beneficial effects on the clinical pathophysiology of heart failure. The aim of the ongoing CANDLE trial is to test the safety and non-inferiority of canagliflozin, another SGLT2 inhibitor, compared with glimepiride, a sulfonylurea agent, in patients with type 2 diabetes mellitus and chronic heart failure.
Methods: A total of 250 patients with type 2 diabetes who are drug-naïve or taking any anti-diabetic agents and suffering from chronic heart failure with a New York Heart Association classification I to III will be randomized centrally into either canagliflozin or glimepiride groups (1: 1) using the dynamic allocation method stratified by age (<65, ≥65 year), HbA1c level (<6.5, ≥6.5 %), and left ventricular ejection fraction (<40, ≥40 %). After randomization, all the participants will be given the add-on study drug for 24 weeks in addition to their background therapy. The primary endpoint is the percentage change from baseline in NT-proBNP after 24 weeks of treatment. The key secondary endpoints after 24 weeks of treatment are the change from baseline in glycemic control, blood pressure, body weight, lipid profile, quality of life score related to heart failure, and cardiac and renal function.
Discussion: The CANDLE trial is the first to assess the safety and non-inferiority of canagliflozin in comparison with glimepiride in patients with type 2 diabetes with chronic heart failure. This trial has the potential to evaluate the clinical safety and efficacy of canagliflozin on heart failure.
Journal Title
Cardiovascular Diabetology
Springer Nature|BioMed Central
Start Page
Published Date
© 2016 Tanaka et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (, which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.
DOI (Published Version)
URL ( Publisher's Version )
FullText File
Medical Sciences